Literature DB >> 17123297

Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women.

Kristy M Borawski1, Raymond T Foster, George D Webster, Cindy L Amundsen.   

Abstract

AIMS: The purpose of this study was to determine whether a percutaneous needle electrode (PNE) technique or a surgical first stage lead placement (FSLP) better predicted whether a patient would progress to implantation of a pulse generator (IPG) in older urge incontinent women.
METHODS: Thirty subjects > or =55 years with refractory urge incontinence who had been selected to undergo a test stimulation procedure were randomized to either PNE or FSLP. Thirteen underwent PNE placement and seventeen underwent FSLP placement. If during the test stimulation period subjects had greater than 50% improvement in their incontinence parameters they qualified for permanent lead and/or IPG implantation of the Interstim device.
RESULTS: Twenty-one subjects (70%) responded to the test stimulation and underwent implantation, 15/17 (88%) in the FSLP group and 6/13 (46%) in the PNE group. Subjects who were randomized to the FSLP group were significantly more likely to proceed to implantation of the IPG (P = 0.02) than those in the PNE group. There was no significant difference in demographics, pre-test stimulation incontinence parameters or post-stimulation visual analog pain scores between the randomized groups or between test stimulation responders and non-responders. When comparing FSLP and PNE responders, there was no significant difference in the percent improvement in 24-hr pad weight, daily pad usage, or daily incontinence.
CONCLUSION: FSLP better predicted progression to implantation of the IPG than a test stimulation with a PNE in an older urge incontinent cohort. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17123297     DOI: 10.1002/nau.20332

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  22 in total

1.  Helping patients with voiding dysfunction: What are our current options?

Authors:  Kurt A McCammon
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

2.  Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela Paraiso; Shawn A Menefee; Joseph Schaffer; John Wei; Toby Chai; Nancy Janz; Cathie Spino; Susan Meikle
Journal:  Contemp Clin Trials       Date:  2011-10-08       Impact factor: 2.226

3.  OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.

Authors:  Cindy L Amundsen; Holly E Richter; Shawn A Menefee; Yuko M Komesu; Lily A Arya; W Thomas Gregory; Deborah L Myers; Halina M Zyczynski; Sandip Vasavada; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  JAMA       Date:  2016-10-04       Impact factor: 56.272

4.  Surgical options for drug-refractory overactive bladder patients.

Authors:  Jonathan S Starkman; Christopher P Smith; David R Staskin
Journal:  Rev Urol       Date:  2010

5.  [Sacral neuromodulation for refractory overactive bladder].

Authors:  Arndt van Ophoven
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

6.  A modified approach to patient's selection with improved clinical outcomes in sacral nerve modulation.

Authors:  Patrick Richard; Maude Carmel; Bechir Hage; Sophie Ramsay; Le Mai Tu
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

Review 7.  Where Are We Headed with Neuromodulation for Overactive Bladder?

Authors:  Kaitlin Jaqua; Charles R Powell
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

Review 8.  Contrasting the percutaneous nerve evaluation versus staged implantation in sacral neuromodulation.

Authors:  Chad Baxter; Ja-Hong Kim
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

9.  Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.

Authors:  Maria Paola Bertapelle; Mario Vottero; Giulio Del Popolo; Marco Mencarini; Edoardo Ostardo; Michele Spinelli; Antonella Giannantoni; Anna D'Ausilio
Journal:  World J Urol       Date:  2014-09-14       Impact factor: 4.226

Review 10.  Understanding clinic options for overactive bladder.

Authors:  Jamie M Bartley; Emily S Blum; Larry T Sirls; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.